185 related articles for article (PubMed ID: 11074181)
1. Efficacy and tolerability of 1000-4000 mg per day of levetiracetam as add-on therapy in patients with refractory epilepsy.
Grant R; Shorvon SD
Epilepsy Res; 2000 Dec; 42(2-3):89-95. PubMed ID: 11074181
[TBL] [Abstract][Full Text] [Related]
2. An open-label study of levetiracetam at individualised doses between 1000 and 3000 mg day(-1) in adult patients with refractory epilepsy.
Abou-Khalil B; Hemdal P; Privitera MD
Seizure; 2003 Apr; 12(3):141-9. PubMed ID: 12651078
[TBL] [Abstract][Full Text] [Related]
3. Evidence for sustained efficacy of levetiracetam as add-on epilepsy therapy.
Ben-Menachem E; Edrich P; Van Vleymen B; Sander JW; Schmidt B
Epilepsy Res; 2003 Feb; 53(1-2):57-64. PubMed ID: 12576168
[TBL] [Abstract][Full Text] [Related]
4. Dose-response effect of levetiracetam 1000 and 2000 mg/day in partial epilepsy.
Boon P; Chauvel P; Pohlmann-Eden B; Otoul C; Wroe S
Epilepsy Res; 2002 Jan; 48(1-2):77-89. PubMed ID: 11823112
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of levetiracetam 1000-3000 mg/day in patients with refractory partial-onset seizures: a multicenter, open-label single-arm study.
Beran RG; Berkovic SF; Black AB; Danta G; Hiersemenzel R; Schapel GJ; Vajda FJ
Epilepsy Res; 2005 Jan; 63(1):1-9. PubMed ID: 15716083
[TBL] [Abstract][Full Text] [Related]
6. A multicentre, double-blind, randomized, parallel group study to evaluate the tolerability and efficacy of two oral doses of levetiracetam, 2000 mg daily and 4000 mg daily, without titration in patients with refractory epilepsy.
Betts T; Waegemans T; Crawford P
Seizure; 2000 Mar; 9(2):80-7. PubMed ID: 10845730
[TBL] [Abstract][Full Text] [Related]
7. Add-on levetiracetam in children and adolescents with refractory epilepsy: results of an open-label multi-centre study.
Callenbach PM; Arts WF; ten Houten R; Augustijn P; Gunning WB; Peeters EA; Weber AM; Stroink H; Geerts Y; Geerts AT; Brouwer OF
Eur J Paediatr Neurol; 2008 Jul; 12(4):321-7. PubMed ID: 17950011
[TBL] [Abstract][Full Text] [Related]
8. Once-daily extended-release levetiracetam as adjunctive treatment of partial-onset seizures in patients with epilepsy: a double-blind, randomized, placebo-controlled trial.
Peltola J; Coetzee C; Jiménez F; Litovchenko T; Ramaratnam S; Zaslavaskiy L; Lu ZS; Sykes DM;
Epilepsia; 2009 Mar; 50(3):406-14. PubMed ID: 19317886
[TBL] [Abstract][Full Text] [Related]
9. Levetiracetam in patients with refractory epilepsy: results of the SKATE trial in Austria, Germany and Switzerland.
Steinhoff BJ; Trinka E; Wieser HG;
Seizure; 2005 Oct; 14(7):490-6. PubMed ID: 16169256
[TBL] [Abstract][Full Text] [Related]
10. Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizures. European Levetiracetam Study Group.
Shorvon SD; Löwenthal A; Janz D; Bielen E; Loiseau P
Epilepsia; 2000 Sep; 41(9):1179-86. PubMed ID: 10999557
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and tolerability of levetiracetam 3000 mg/d in patients with refractory partial seizures: a multicenter, double-blind, responder-selected study evaluating monotherapy. European Levetiracetam Study Group.
Ben-Menachem E; Falter U
Epilepsia; 2000 Oct; 41(10):1276-83. PubMed ID: 11051122
[TBL] [Abstract][Full Text] [Related]
12. A paradoxical effect of levetiracetam may be seen in both children and adults with refractory epilepsy.
Nakken KO; Eriksson AS; Lossius R; Johannessen SI
Seizure; 2003 Jan; 12(1):42-6. PubMed ID: 12495648
[TBL] [Abstract][Full Text] [Related]
13. Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in Chinese patients with refractory partial-onset seizures.
Wu XY; Hong Z; Wu X; Wu LW; Wang XF; Zhou D; Zhao ZX; Lv CZ
Epilepsia; 2009 Mar; 50(3):398-405. PubMed ID: 18657175
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of levetiracetam as adjunctive treatment for refractory canine epilepsy: a randomized, placebo-controlled, crossover trial.
Muñana KR; Thomas WB; Inzana KD; Nettifee-Osborne JA; McLucas KJ; Olby NJ; Mariani CJ; Early PJ
J Vet Intern Med; 2012; 26(2):341-8. PubMed ID: 22295869
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of levetiracetam: a review of three pivotal clinical trials.
Privitera M
Epilepsia; 2001; 42 Suppl 4():31-5. PubMed ID: 11564123
[TBL] [Abstract][Full Text] [Related]
16. Levetiracetam in a broad population of patients with refractory epilepsy: interim results of the international SKATE trial.
Genton P; Sadzot B; Fejerman N; Peltola J; Despland PA; Steinhoff B; Rektor I; Wroe S; Maubrey MC; Vandervelden C; van Hammée G; Schlit AF; van Paesschen W
Acta Neurol Scand; 2006 Jun; 113(6):387-94. PubMed ID: 16674605
[TBL] [Abstract][Full Text] [Related]
17. The SKATE study: an open-label community-based study of levetiracetam as add-on therapy for adults with uncontrolled partial epilepsy.
Steinhoff BJ; Somerville ER; Van Paesschen W; Ryvlin P; Schelstraete I
Epilepsy Res; 2007 Aug; 76(1):6-14. PubMed ID: 17681453
[TBL] [Abstract][Full Text] [Related]
18. [Efficacy and safety of levetiracetam (keppra) add-on treatment in adult patients with refractory epilepsy in two tertiary centers].
Auriel E; Chistik V; Blatt I; Margolin N; Neufeld M
Harefuah; 2007 Apr; 146(4):269-71, 318. PubMed ID: 17476932
[TBL] [Abstract][Full Text] [Related]
19. Levetiracetam for partial seizures: results of a double-blind, randomized clinical trial.
Cereghino JJ; Biton V; Abou-Khalil B; Dreifuss F; Gauer LJ; Leppik I
Neurology; 2000 Jul; 55(2):236-42. PubMed ID: 10908898
[TBL] [Abstract][Full Text] [Related]
20. Long-term levetiracetam treatment of epilepsy patients: clinical audit.
Kuba R; Novotná I; Brázdil M; Kocvarová J; Tyrliková I; Mastík J; Rektor I
Epilepsy Res; 2006 Dec; 72(2-3):111-9. PubMed ID: 16930945
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
